Welcome to Prof. Junho Chung's Laboratory


We create novel therapeutic antibodies and biopharmaceuticals.  An anti-hepatocyte growth factor (HGF)-neutralizing antibody (YYB101 OR NOV1105, nov.ncc.re.kr/eng/) is in phase II clinical trial (NCT04368507). A few more antibodies and CAR (chimeric antigen receptor) T cell therapies are under pre-clinical development and expected to enter clinical phase in 2021.


We invent novel platform technologies in the field of bispecific antibodies, antibody drug conjugate (ADC) and CAR T cell therapy. Anti-cotinine antibody is now used for a new form of switchable CAR T cell therapy and ADC.


We develop algorithms for deciphering B cell repertoire of human and animals using Machine learning and Next Generation Sequencing (NGS) technology. This research provides us valuable information on the immunological process of viral infection, autoimmune disease and carcinogenesis.




Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine

Department of Biomedical Sciences, Seoul National University College of Medicine

Laboratory of Antibody Engineering, Cancer Research Institute, Seoul National University



Suites 506-515, Samsung Cancer Research Building

Daehakro 103, Seoul 03080, South Korea (Rep. of Korea)

Last Update: 25 Jan  2021